CN116940333A - Cosmetic composition for improving skin by regulating porphyrin production of skin resident bacteria and regulating hyaluronidase - Google Patents
Cosmetic composition for improving skin by regulating porphyrin production of skin resident bacteria and regulating hyaluronidase Download PDFInfo
- Publication number
- CN116940333A CN116940333A CN202280016884.2A CN202280016884A CN116940333A CN 116940333 A CN116940333 A CN 116940333A CN 202280016884 A CN202280016884 A CN 202280016884A CN 116940333 A CN116940333 A CN 116940333A
- Authority
- CN
- China
- Prior art keywords
- skin
- cosmetic composition
- propionibacterium acnes
- inhibiting
- acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 150000004032 porphyrins Chemical class 0.000 title claims abstract description 41
- 239000002537 cosmetic Substances 0.000 title claims abstract description 34
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 24
- 108010003272 Hyaluronate lyase Proteins 0.000 title claims description 12
- 102000001974 Hyaluronidases Human genes 0.000 title claims description 11
- 229960002773 hyaluronidase Drugs 0.000 title claims description 11
- 230000001105 regulatory effect Effects 0.000 title claims description 9
- 241000894006 Bacteria Species 0.000 title abstract description 23
- 229920002674 hyaluronan Polymers 0.000 claims abstract description 35
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims abstract description 30
- 229960003160 hyaluronic acid Drugs 0.000 claims abstract description 30
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 24
- 238000000354 decomposition reaction Methods 0.000 claims abstract description 14
- 244000005714 skin microbiome Species 0.000 claims abstract description 8
- 210000003491 skin Anatomy 0.000 claims description 63
- 241000186427 Cutibacterium acnes Species 0.000 claims description 48
- 229940055019 propionibacterium acne Drugs 0.000 claims description 47
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 32
- 206010000496 acne Diseases 0.000 claims description 32
- 244000005700 microbiome Species 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 9
- 150000001720 carbohydrates Chemical class 0.000 claims description 9
- 229940094944 saccharide isomerate Drugs 0.000 claims description 7
- 229960003495 thiamine Drugs 0.000 claims description 7
- JZRWCGZRTZMZEH-UHFFFAOYSA-N Thiamine Natural products CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N JZRWCGZRTZMZEH-UHFFFAOYSA-N 0.000 claims description 6
- 230000036542 oxidative stress Effects 0.000 claims description 6
- 235000019157 thiamine Nutrition 0.000 claims description 6
- 239000011721 thiamine Substances 0.000 claims description 6
- KYMBYSLLVAOCFI-UHFFFAOYSA-N thiamine Chemical compound CC1=C(CCO)SCN1CC1=CN=C(C)N=C1N KYMBYSLLVAOCFI-UHFFFAOYSA-N 0.000 claims description 6
- 241000928573 Cutibacterium Species 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 208000024891 symptom Diseases 0.000 claims description 3
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 241000300894 Propionibacterium acnes HL053PA1 Species 0.000 claims description 2
- 241000300919 Propionibacterium acnes HL110PA3 Species 0.000 claims description 2
- 210000004207 dermis Anatomy 0.000 claims description 2
- 230000036620 skin dryness Effects 0.000 claims description 2
- 230000037394 skin elasticity Effects 0.000 claims description 2
- 206010048222 Xerosis Diseases 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 37
- 102000004190 Enzymes Human genes 0.000 abstract description 10
- 108090000790 Enzymes Proteins 0.000 abstract description 10
- 230000006872 improvement Effects 0.000 abstract description 6
- 230000000593 degrading effect Effects 0.000 abstract description 5
- 230000036541 health Effects 0.000 abstract description 4
- 230000002939 deleterious effect Effects 0.000 abstract description 3
- 230000002411 adverse Effects 0.000 abstract description 2
- 230000032683 aging Effects 0.000 abstract description 2
- 230000002500 effect on skin Effects 0.000 abstract description 2
- 231100000989 no adverse effect Toxicity 0.000 abstract 1
- 230000036559 skin health Effects 0.000 abstract 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 14
- 241000191967 Staphylococcus aureus Species 0.000 description 13
- 229960000344 thiamine hydrochloride Drugs 0.000 description 13
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 13
- 239000011747 thiamine hydrochloride Substances 0.000 description 13
- 238000002474 experimental method Methods 0.000 description 11
- 230000001717 pathogenic effect Effects 0.000 description 10
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- 229940088598 enzyme Drugs 0.000 description 9
- -1 for example Substances 0.000 description 9
- 230000036074 healthy skin Effects 0.000 description 8
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000033228 biological regulation Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 150000003544 thiamines Chemical class 0.000 description 7
- 206010061218 Inflammation Diseases 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 230000009286 beneficial effect Effects 0.000 description 5
- 235000014113 dietary fatty acids Nutrition 0.000 description 5
- 239000000194 fatty acid Substances 0.000 description 5
- 229930195729 fatty acid Natural products 0.000 description 5
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 5
- 229940099552 hyaluronan Drugs 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 230000035755 proliferation Effects 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 230000003902 lesion Effects 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 241000416162 Astragalus gummifer Species 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 3
- 229920001615 Tragacanth Polymers 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 235000011187 glycerol Nutrition 0.000 description 3
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 230000009545 invasion Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000000344 soap Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000196 tragacanth Substances 0.000 description 3
- 235000010487 tragacanth Nutrition 0.000 description 3
- 229940116362 tragacanth Drugs 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 239000001993 wax Substances 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 206010012434 Dermatitis allergic Diseases 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 208000001388 Opportunistic Infections Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 239000003899 bactericide agent Substances 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- KQNPFQTWMSNSAP-UHFFFAOYSA-N isobutyric acid Chemical compound CC(C)C(O)=O KQNPFQTWMSNSAP-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 244000005706 microflora Species 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 230000037311 normal skin Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 101150079601 recA gene Proteins 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 208000017520 skin disease Diseases 0.000 description 2
- 239000007974 sodium acetate buffer Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- STGNLGBPLOVYMA-MAZDBSFSSA-N (E)-but-2-enedioic acid Chemical compound OC(=O)\C=C\C(O)=O.OC(=O)\C=C\C(O)=O STGNLGBPLOVYMA-MAZDBSFSSA-N 0.000 description 1
- STGNLGBPLOVYMA-TZKOHIRVSA-N (z)-but-2-enedioic acid Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O STGNLGBPLOVYMA-TZKOHIRVSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- PUDVULIQIRMBCA-UHFFFAOYSA-N 2-methylbenzenesulfonic acid;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=CC=C1S(O)(=O)=O PUDVULIQIRMBCA-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- MDBVZFGSKMWJFD-UHFFFAOYSA-N OP(O)=O.OP(O)(O)=O Chemical compound OP(O)=O.OP(O)(O)=O MDBVZFGSKMWJFD-UHFFFAOYSA-N 0.000 description 1
- CJXGDWDDLMZNBC-UHFFFAOYSA-N P(O)(O)=O.P(O)(O)O Chemical compound P(O)(O)=O.P(O)(O)O CJXGDWDDLMZNBC-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010048038 Wound infection Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 150000003862 amino acid derivatives Chemical class 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 238000003287 bathing Methods 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- ILAJWURWJKXJPW-UHFFFAOYSA-N butanedioic acid;octanedioic acid Chemical compound OC(=O)CCC(O)=O.OC(=O)CCCCCCC(O)=O ILAJWURWJKXJPW-UHFFFAOYSA-N 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 238000005810 carbonylation reaction Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000000306 component Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 235000012343 cottonseed oil Nutrition 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- HHFAWKCIHAUFRX-UHFFFAOYSA-N ethoxide Chemical compound CC[O-] HHFAWKCIHAUFRX-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- 239000003228 hemolysin Substances 0.000 description 1
- 244000005702 human microbiome Species 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000008798 inflammatory stress Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical class OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- NIFHFRBCEUSGEE-UHFFFAOYSA-N oxalic acid Chemical compound OC(=O)C(O)=O.OC(=O)C(O)=O NIFHFRBCEUSGEE-UHFFFAOYSA-N 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- ZFACJPAPCXRZMQ-UHFFFAOYSA-N phthalic acid Chemical compound OC(=O)C1=CC=CC=C1C(O)=O.OC(=O)C1=CC=CC=C1C(O)=O ZFACJPAPCXRZMQ-UHFFFAOYSA-N 0.000 description 1
- 238000013081 phylogenetic analysis Methods 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- HJSRRUNWOFLQRG-UHFFFAOYSA-N propanedioic acid Chemical compound OC(=O)CC(O)=O.OC(=O)CC(O)=O HJSRRUNWOFLQRG-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 230000006318 protein oxidation Effects 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000002374 sebum Anatomy 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 230000008591 skin barrier function Effects 0.000 description 1
- 230000036555 skin type Effects 0.000 description 1
- 239000008234 soft water Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 229940100615 topical ointment Drugs 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/673—Vitamin B group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present disclosure provides a cosmetic composition capable of healthy rebalancing of a skin microbiome without affecting the growth of skin resident bacteria that have no adverse effect on skin health while reducing the growth of skin resident bacteria that are adverse to skin health and the production of the deleterious factor porphyrin (porphyrins). The present disclosure also provides a cosmetic composition capable of inhibiting porphyrin production by a porphyrin-producing strain. The present disclosure also provides a skin improvement composition that inhibits decomposition of hyaluronic acid in skin by inhibiting the activity of hyaluronic acid degrading enzymes secreted by skin resident bacteria, thereby helping to preserve moisture and prevent aging.
Description
Technical Field
The present application claims priority based on korean application No. 10-2021-0028329, filed on 3 months of 2021, and all matters disclosed in the specification and drawings of this application are incorporated herein.
The present application relates to a cosmetic composition capable of advantageously regulating (rebalancing) the growth and metabolism (metanolome) of skin resident bacteria. The present application also relates to a cosmetic composition capable of inhibiting the production of skin-harmful substances (for example, inhibiting the production of porphyrin by a porphyrin-producing strain, etc.), and inhibiting the hyaluronic acid-decomposing ability of a strain secreting a hyaluronic acid-decomposing enzyme.
Background
There are millions of bacteria, molds and viruses on the skin that make up the skin microbiome (skin microbiome). Microbiome (Microbiome) refers to the sum of microorganisms present in a particular environment. The presence of genes of microorganisms present in humans in hundreds of times the human genes affects various functions in humans.
It is known that a large part of the human microbiota is present in the intestinal tract, but that a variety of microorganisms are also present in the skin. Microorganisms present in the skin are also known to play an essential role in various metabolism of pathogenic bacteria invasion, immune system regulation, natural substance decomposition, etc., similar to those in the intestinal tract, and may affect the health state of a person. The skin, which is the largest organ of the human body, is colonized by beneficial microorganisms and serves as a physical barrier against pathogenic bacteria invasion. Skin diseases or systemic diseases may occur when the barrier is weakened or the balance between the symbiont and the pathogen is broken. Research into the composition of microbiota at the skin site of humans helps reveal the etiology of common skin diseases or the association with skin conditions.
When a bactericide or an antibiotic having a strong bactericidal action, which is capable of removing all the indigenous microflora of the skin, is used, there is a risk that bacteria that have a beneficial effect on the skin may also be removed, and the appearance and proliferation of resistant bacteria to the component may be promoted. In addition, when the use of bactericides or antibiotics is stopped, since the existing skin colony balance is broken, there is a risk that bacteria which are not ideal for the skin may preferentially grow and induce opportunistic infections and the like. When a substance capable of selectively regulating colonies is used instead of a broad-spectrum antibiotic, the proportion of bacteria having beneficial effects on the skin can be increased while avoiding a wide range of side effects on the indigenous microflora of the skin.
That is, a breakdown in the balance between beneficial and harmful bacteria present in the skin may induce opportunistic infections. Thus, maintaining the balance between microorganisms is an important part of maintaining a healthy skin state.
Propionibacterium acnes (Cutibacterium acne, c.acre) break down sebum into glycerin and fatty acids in order to maintain the skin weakly acidic, and act to inhibit invasion or growth of pathogenic bacteria. Is one of the main strains often residing on the skin and plays an important role in maintaining the skin barrier. Therefore, it is not preferable to apply an antibiotic having an antibacterial or bactericidal effect, which may affect the whole propionibacterium acnes, to the skin.
Recently, phylogenetic analyses of acne bacteria have been performed, clearly knowing that there are strains of propionibacterium acnes (Cutibacterium acne) that are mainly present in healthy people and not in acne patient groups, and strains of propionibacterium acnes that are mainly present in acne patients and not in healthy skin. In addition, propionibacterium acnes differ in the nature of harmful molecules such as systemic secretion proteases, lipases, hemolysins, porphyrins (porphyrins) and the like, and induce skin harmful reactions by these which can decompose host tissues or induce inflammatory reactions and the like.
For example, for porphyrin numbers, higher was observed in acne skin compared to healthy skin and higher was observed in acne lesions compared to non-lesions of acne patients. In particular, propionibacterium acnes strains of the acne-related system are known to produce higher concentrations of porphyrins. In addition, it is known that porphyrin can be produced also against staphylococcus aureus (s. Aureus) which has a problem in allergic dermatitis, wound infection, and the like.
Porphyrins not only induce oxidative stress in the skin, promote the expression of inflammatory cytokines by keratinocytes, but also induce a carbonylation reaction that is one of protein oxidation, thereby darkening the skin tone and making the skin look unhealthy. Therefore, it is used as one measurement index in various skin measuring instruments and needs to be regulated as one of the main detrimental factors of skin microorganisms.
Disclosure of Invention
Technical problem
Accordingly, an object of the present application is to provide a cosmetic composition capable of suppressing skin resident bacteria (e.g., a specific propionibacterium acnes strain) that have a relatively adverse effect on the skin (e.g., cause acne, etc.), while the growth of skin resident bacteria (e.g., a specific propionibacterium acnes strain) that have no much effect on the skin is relatively less, thereby rebalancing the skin resident bacteria colonies.
Another object of the present application is to provide a skin improving composition which can regulate skin-damaging factors inducing oxidative stress, inflammation, and the like of the skin by inhibiting the production of porphyrin secreted by microorganisms present in the skin.
In addition, a skin improvement composition capable of preventing decomposition of hyaluronic acid by inhibiting a hyaluronic acid decomposing enzyme secreted by a microorganism is provided.
Technical proposal
In order to solve the above-described problems, the present disclosure provides a cosmetic composition for regulating skin microbiome (microbiome) comprising any one or more selected from the group consisting of thiamine or a cosmetically acceptable salt thereof and saccharide isomer (saccharide isomerate) as an active ingredient.
Another aspect of the present disclosure provides a cosmetic composition for modulating propionibacterium acnes in a skin microbiome (microbiome) comprising any one or more selected from the group consisting of thiamine or a cosmetically acceptable salt thereof and saccharide isomer (saccharide isomerate) as an active ingredient.
According to one aspect of the present disclosure, the cosmetic composition of the present application may be used for improving skin by modulating porphyrin production and/or modulating hyaluronan degrading enzymes in skin resident bacteria. Accordingly, one aspect of the present disclosure provides a skin improvement composition that modulates skin deleterious factors that induce oxidative stress and inflammation of the skin, etc., by inhibiting the production of porphyrin secreted by microorganisms present in the skin. Another aspect of the present disclosure provides a skin improvement composition capable of preventing hyaluronic acid from being decomposed by inhibiting a hyaluronic acid decomposing enzyme secreted by a microorganism.
Preferably, the above cosmetic composition of the present disclosure contains thiamine or a cosmetically acceptable salt thereof as an active ingredient.
The present inventors have conducted tests on various substances such as amino acids, amino acid derivatives, extracts, saccharides, vitamins, perfume ingredients, etc., and confirmed that only the compounds of the present application exhibit the desired effects of the present application, thereby completing the present application.
According to Fitz-Gibbon, s.etc. (2013) Propionibacterium acnes Strain Populations in the Human Skin Microbiome Associated with acne. Journal of Investigative Dermatology,133 (9), 2152-2160, etc., propionibacterium acnes, one of the skin resident bacteria, can be classified into the following categories, of which RT4 and RT5 are known to be acne-inducing based on ribotyping (ribotype), and RT6 is known to be present in a large amount in healthy skin.
TABLE 1
| Ribosome type (Ribotype) | RT4 (e.g., HL053PA1 strain) | RT6 (example)E.g., HL110PA3 strain) |
| Acne induction | Has the following components | Without any means for |
| Culture speed | Slow (6 days) | Moderate (4 days) |
| Porphyrin production | High (500 nM) | Low (about 30 nM) |
| HA decomposition ability | Low and low | Very high |
HL053PA1 strain and the like produce excessive amounts of porphyrins that can induce inflammation and oxidative stress, and as such, can cause inflammation such as acne by inducing secretion of inflammatory cytokines in the skin. The cosmetic compositions of the present disclosure inhibit the growth of acne-induced types (e.g., RT4 or RT5, type IA based on recA) in propionibacterium acnes, while having relatively no effect on the growth of acne-non-induced types (e.g., RT 6), so that the microbiome ecology of dominant species can be maintained.
Furthermore, the cosmetic composition of the present disclosure inhibits porphyrin production of skin resident bacteria, particularly porphyrin production of acne-induced propionibacterium acnes strain or porphyrin production of strains such as staphylococcus aureus, thereby greatly contributing to inhibition of acne induction, or increase of dermal density of skin, or improvement of skin dryness symptoms, or improvement of skin color.
According to recent studies, it was shown that strains belonging to RT6 (or recA-based type II) produce relatively few harmful factors such as porphyrins, but can produce excessive amounts of hyaluronidase. In addition, it is known that various bacteria such as staphylococcus aureus can produce hyaluronan degrading enzymes.
In this regard, the cosmetic composition of the present disclosure may exhibit a very advantageous effect as a cosmetic composition for improving skin elasticity or the like by inhibiting hyaluronic acid decomposition of skin resident bacteria, in particular, inhibiting hyaluronic acid decomposition caused by propionibacterium acnes strain or staphylococcus aureus. The inhibition of the hyaluronic acid decomposition ability also improves the dermis density, and also shows good effects in the aspects of moisture retention, aging prevention and the like.
In the present application, "cosmetically acceptable salts" include salts of the active compounds prepared with relatively non-toxic acids. Acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of the desired acid, pure or suitable inert (insert) solvent. Examples of cosmetically acceptable acid addition salts include not only salts derived from relatively nontoxic organic acids including acetic acid, propionic acid, isobutyric acid, oxalic acid (oxalic acid), maleic acid (maleic acid), malonic acid (malonic acid), benzoic acid, succinic acid, suberic acid (succinic acid), fumaric acid (fumaric acid), mandelic acid (mandelc), phthalic acid (phthalic acid), benzenesulfonic acid (benzenesulfonic), p-toluenesulfonic acid (tolylsulfonic acid), citric acid, tartaric acid, methanesulfonic acid (methanesulfonic acid) and the like, but also hydrogen chloride, hydrogen bromide, nitric acid, carbonic acid, monohydrocarbonic acid (monohydrogencarbonic acid), phosphoric acid (phosphonic acid), monohydrogen phosphoric acid, dihydrogen phosphoric acid, sulfuric acid, monohydrogen sulfuric acid, hydrogen iodide or phosphorous acid (phosphonic acid) and the like. Also included are salts of amino acids, such as arginine (arginate) and analogs thereof, and analogs of organic acids, such as glucuronic acid (glucuronic) or galacturonic acid (galacturonic) and analogs thereof. Other examples of salts can be found in the literature known in the art to which the present application pertains.
In the cosmetic composition of the present application, the total content of the above-mentioned active ingredients is preferably 0.00001 to 10% by weight based on the total weight of the cosmetic composition.
The active ingredient of the present application may exist not only in a solvated form including a hydrate, an ethanolate and the like, but also in a non-solvated (unsolvated) form. The active ingredient of the present application can exist in a crystalline or amorphous form, and all such physical forms are included within the scope of the present application.
The cosmetic composition of the present application may be prepared into a dosage form selected from the group consisting of a solution, a topical ointment, a cream, a foam, a nutritional lotion, a skin softening lotion, a mask, a soft water, an emulsion, a pre-makeup base, an essence, a soap, a liquid cleansing, a bathing agent, a sun cream, a sun oil, a suspension, an emulsion, a paste, a gel, a lotion, a powder, a soap, a surfactant-containing cleansing agent, an oil, a powder foundation, an emulsion foundation, a wax foundation, a patch, and a spray, but is not limited thereto.
The cosmetic composition of the present application may further comprise one or more cosmetically acceptable carriers blended in a normal skin cosmetic, and as a conventional ingredient, for example, oil, water, surfactant, moisturizer, lower alcohol, thickener, chelating agent, pigment, preservative, perfume, etc. may be suitably blended, but is not limited thereto.
The cosmetically acceptable carrier contained in the cosmetic composition of the present application is various depending on the dosage form. When the dosage form of the present application is an ointment, paste, cream or gel, as a carrier component, animal oil, vegetable oil, wax (wax), paraffin (Paraffin), starch, tragacanth (tragacanth), cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide or mixtures thereof can be used.
When the dosage form of the present application is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, polyamide powder or mixtures thereof can be used as carrier ingredients, and in particular, when a spray is used, propellants such as chlorofluorocarbons, propane/butane or dimethyl ether can be additionally contained.
When the dosage form of the present application is a solution or emulsion, as a carrier component, a solvent, a solubilizing agent (solubilizer), or an opacifying agent, such as water, ethanol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl benzoate, propylene glycol, 1, 3-butyl glycol oil, particularly cotton seed oil, peanut oil, corn seed oil, olive oil, castor oil and sesame oil, glycerin fatty ester, polyethylene glycol or fatty acid ester of sorbitan is used.
When the dosage form of the present application is a suspension, as the carrier component, there may be used liquid diluents such as water, ethanol or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar-agar or tragacanth, and the like.
When the dosage form of the present application is a soap, alkali metal salts of fatty acids, fatty acid half ester salts, fatty acid protein hydrolysates, isethionates, lanolin derivatives, fatty alcohols, vegetable oils, glycerin, sugar, and the like can be used as carrier components.
All the components described in the present application preferably do not exceed the maximum use value specified in the relevant regulations and regulations such as korea, china, united states, europe, japan, etc. (for example, relevant regulations such as cosmetic safety standards (korea), cosmetic safety technical regulations (china), food act (korea), food additive act (korea), health function act (korea), health regulations (china)), etc. That is, the cosmetic, food or personal care composition of the present application preferably includes the components of the present application within the content limits allowed in the relevant regulations and specifications of each country.
Effects of the application
The compositions, particularly cosmetic compositions, provided in the present disclosure exhibit the effect of inhibiting the growth of the propionibacterium acnes type that is frequently present in patients suffering from acne in the skin's predominant resident bacteria, such as propionibacterium acnes, and the production of deleterious factors (porphyrins). In addition, it is also possible to exhibit an effect of inhibiting the activity of hyaluronidase (hyaluronidase) produced by the strain without affecting the growth of propionibacterium acnes type which is mainly present in non-inflammatory skin. In addition, it is also possible to exhibit an effect of inhibiting porphyrin production and/or hyaluronidase (hyaluronidase) activity produced by bacteria present in the skin such as staphylococcus aureus other than propionibacterium acnes.
Drawings
The following drawings accompanying the present specification illustrate preferred embodiments of the present application and, together with the description of the application given above, serve to further understand the technical idea of the present application, and therefore the present application should not be construed as being limited to only those matters described in these drawings.
FIG. 1 is a graph of the results of evaluating the effect of thiamine salts on pathogenic strains of Propionibacterium acnes.
FIG. 2 is a result of evaluating the effect of thiamine salts on non-pathogenic strains of Propionibacterium acnes.
FIG. 3 is a result of evaluating the effect of thiamine salts on porphyrin production by pathogenic and non-pathogenic strains of Propionibacterium acnes.
FIG. 4 is a graph showing the results of evaluating the effect of thiamine salts on porphyrin production by Staphylococcus aureus strains.
FIG. 5 is a result of evaluating the effect of thiamine salts on the hyaluronic acid decomposing ability of non-pathogenic strains of Propionibacterium acnes.
FIG. 6 is a graph showing the results of evaluating the effect of thiamine salts on the hyaluronic acid decomposing ability of Staphylococcus aureus strains.
FIG. 7 is a result of evaluating the effect of saccharide isomerate on the growth of propionibacterium acnes pathogenic and nonpathogenic strains and on porphyrin production of propionibacterium acnes pathogenic strains. In fig. 7, a is a result of evaluating an effect on the strain growth of the propionibacterium acnes strain HL053PA1 related to acne skin, b is a result of evaluating an effect on the strain growth of the propionibacterium acnes strain HL110PA3 related to healthy skin, c is a result of evaluating an effect on the porphyrin production of the propionibacterium acnes strain HL053PA1 related to acne skin, and d is a result of evaluating an effect on the hyaluronic acid decomposition rate of the propionibacterium acnes strain HL110PA3 related to healthy skin.
Detailed Description
Hereinafter, in order to assist understanding of the present application, detailed description will be made of exemplary embodiments and the like. However, the embodiments of the present application may be modified into various forms, and the scope of the present application should not be construed as being limited to the following embodiments. Embodiments of the present application are provided to more fully describe the present application to those of ordinary skill in the art to which the present application pertains.
For reference, the following experimental methods are carried out except for the specifically mentioned materials and methods in the paper "Vitamin B12modulates the transcriptome of the skin microbiota in acne pathogenesis" (Sci Transl Med.2015Jun 24;7 (293): 293ra103.Doi:10.1126/scitranslmed. Aab 2009.) or "The Skin Bacterium Propionibacterium acnes Employs Two Variants of Hyaluronate Lyase with Distinct Properties" (microorganisms.2017 Sep 12;5 (3): 57.Doi:10.3390/microorganisms 5030057).
1. Inhibition of Propionibacterium acnes strain growth (FIG. 1)
The experimental method comprises the following steps: experiments were performed to confirm the effect of Thiamine HCl on the proliferation of propionibacterium acnes associated with acne.
Propionibacterium acnes type HL053PA1 strain mainly present in acne patients was cultured and activated in BHI broth, and then re-inoculated at the same turbidity. At this time, thiamine hydrochloride was treated at a concentration of 1w/v% and cultured for 7 days, and then absorbance was measured at 595nm to confirm the effect on strain proliferation. The results are shown in FIG. 1.
Results: it was confirmed that thiamine hydrochloride treatment reduced growth by about 70% compared with untreated group, thereby inhibiting the growth of propionibacterium acnes which mainly released harmful factors.
2. Propionibacterium acnes strain growth related to ordinary skin (FIG. 2)
The experimental method comprises the following steps: experiments were performed to confirm the effect of thiamine hydrochloride on the proliferation of propionibacterium acnes, which is mainly present only in normal skin without inflammation (e.g. acne).
Propionibacterium acnes type HL110PA3 strain, which is mainly present only in ordinary skin, was cultured and activated in BHI liquid medium, and then re-inoculated at the same turbidity. At this time, thiamine hydrochloride was treated at a concentration of 1% and cultured for 7 days, and then absorbance was measured at 595nm to confirm the effect on strain proliferation. The results are shown in FIG. 2.
Results: when thiamine hydrochloride is treated, the growth of the propionibacterium acnes type of the ordinary skin type is not greatly affected compared with the growth of the propionibacterium acnes type which is related to the acne is remarkably reduced.
3. Effect of inhibiting porphyrin production (fig. 3)
The experimental method comprises the following steps: experiments were performed to confirm the effect on porphyrins (porphyrins) known to induce oxidative stress and to participate in inflammation such as acne in the skin.
Propionibacterium acnes HL053PA1 and HL110PA3 strains were cultured and activated in BHI broth, respectively, and then re-inoculated at the same turbidity. At this time, thiamine hydrochloride was treated at 1% concentration and cultured for 7 days, and then the strain culture was recovered. Ethyl acetate and acetic acid (4:1, vol/vol) were added to extract 400. Mu.l of bacterial culture. The extract was centrifuged and the upper porphyrin-containing layer was recovered by layer separation. To the recovered supernatant, 1.5M HCl was added for dissolution, and layer separation was performed by centrifugation, thereby recovering the lower layer. Fluorescence measurements were performed at 405nm/620nm for the recovered soluble phase. The results are shown in FIG. 3.
Results: the propionibacterium acnes strain associated with acne produces a large amount of porphyrins compared to propionibacterium acnes strain present in ordinary skin. When thiamine hydrochloride was treated, the amount of porphyrin present in the culture of acne-related strain HL053PA1 was significantly reduced.
4. Porphyrin production inhibitory Effect in other porphyrin-producing Strain (FIG. 4)
Staphylococcus aureus strains were grown and activated in BHI broth to be re-inoculated at 1/100 concentration. Thiamine hydrochloride was treated at a concentration of 1w/v% and cultured for 24 hours, and then the strain culture was recovered. Ethyl acetate and acetic acid (4:1, vol/vol) were added to extract 400. Mu.l of bacterial culture. The extract was centrifuged and the upper porphyrin-containing layer was recovered by layer separation. To the recovered supernatant, 1.5M HCl was added for dissolution, and layer separation was performed by centrifugation, thereby recovering the lower layer. Fluorescence measurements were performed at 405nm/620nm for the recovered soluble phase. The results are shown in FIG. 4.
Results: when thiamine hydrochloride is treated, the amount of porphyrin secreted by staphylococcus aureus is significantly reduced.
5. Efficacy of inhibiting hyaluronic acid decomposition (FIG. 5)
The experimental method comprises the following steps: experiments were performed to confirm whether the activity of the hyaluronidase secreted by the ordinary skin-related propionibacterium acnes strain HL110PA3 was inhibited.
HL110PA3 strain was cultured and activated in BHI broth, and then re-inoculated at the same turbidity. At this time, thiamine hydrochloride was treated at a concentration of 1% and cultured for 7 days, and then the culture broth was recovered. To determine the activity of the hyaluronan-degrading enzyme secreted by propionibacterium acnes, hyaluronic acid and the culture broth were mixed and reacted at 37℃for 20 minutes. After completion of the reaction, 1% BSA sodium acetate buffer (sodium acetate buffer) was added to coagulate the remaining hyaluronic acid and BSA, and the absorbance was taken at 540nm to confirm the degree of decomposition of the hyaluronic acid. The results are shown in FIG. 5.
Results: propionibacterium acnes non-pathogenic strain HL110PA3 is isolated from healthy skin without inflammatory lesions and is therefore generally classified as propionibacterium acnes of healthy skin, but as shown in the experimental results, secretes a hyaluronan degrading enzyme and thus can degrade hyaluronic acid in the skin. It was confirmed that about 85% of the hyaluronic acid was decomposed within 20 minutes when the untreated culture medium was treated, whereas about 60% of the hyaluronic acid was decomposed in the culture medium of the experimental group treated with thiamine hydrochloride, and about 30% of the hyaluronic acid was suppressed from being decomposed in comparison with the control group.
6. Hyaluronic acid decomposition inhibition efficacy in other strains secreting hyaluronidase (FIG. 6)
The experimental method comprises the following steps: experiments were performed to determine whether the activity of the hyaluronan degrading enzyme of staphylococcus aureus was inhibited.
Staphylococcus aureus strains were grown and activated in BHI broth to be re-inoculated at 1/100 concentration. Thiamine hydrochloride was treated at a concentration of 1% and cultured for 24 hours, and then the strain culture solution was recovered. To determine the activity of hyaluronan-degrading enzyme secreted by Staphylococcus aureus, hyaluronic acid was mixed with the culture broth and reacted at 37℃for 90 minutes. To determine the remaining hyaluronic acid without decomposition, the remaining hyaluronic acid was quantified using the hyaluronic acid ELISA (hyaluronan ELISA) kit.
Results: staphylococcus aureus, which is found to have a high frequency in allergic dermatitis lesions and the like, can decompose hyaluronic acid. It was confirmed that when the untreated culture medium was treated, 50% or more of the hyaluronic acid was decomposed, whereas when the culture medium of the experimental group treated with thiamine hydrochloride was less than 10% of the hyaluronic acid was decomposed, the decomposition of hyaluronic acid was significantly suppressed.
7. Evaluation results of saccharide isomers (FIG. 7)
The effect of saccharide isomers on the growth of propionibacterium acnes pathogenic and nonpathogenic strains was evaluated in the same manner as the thiamine salts described above. The results are shown in FIG. 7. As saccharide isomers, use is made ofAnd (5) a product.
As shown in fig. 7, it was confirmed that saccharide isomers also inhibit the growth of harmful propionibacterium acnes that induce acne, while the growth inhibition of beneficial propionibacterium acnes is relatively small, thus having the effect of rebalancing the strain. In addition, it was confirmed that the compound exhibits an inhibitory effect on the production of porphyrin and the production of hyaluronidase.
Claims (7)
1. A cosmetic composition for regulating skin microbiome (microbiome) comprising any one or more selected from the group consisting of thiamine or a cosmetically acceptable salt thereof and saccharide isomer (saccharide isomerate) as an active ingredient.
2. The cosmetic composition of claim 1, wherein the cosmetic composition is used for modulating propionibacterium acnes (Cutibacterium acne) in a skin microbiome (microbiome).
3. A cosmetic composition according to claim 2, wherein said composition inhibits the growth of propionibacterium acnes HL053PA1 strain more than propionibacterium acnes HL110PA3 strain.
4. A cosmetic composition for inhibiting porphyrin production by microorganisms, comprising any one or more selected from the group consisting of thiamine or a cosmetically acceptable salt thereof and saccharide isomer (saccharide isomerate) as an active ingredient.
5. A cosmetic composition according to claim 3, wherein the cosmetic composition is used for inhibiting oxidative stress of skin, or improving skin inflammation, or inhibiting acne induction, or increasing dermis density, or improving xerosis cutis symptoms, or improving skin tone.
6. A cosmetic composition for inhibiting a hyaluronidase secreted by a microorganism, comprising any one or more selected from the group consisting of thiamine or a cosmetically acceptable salt thereof and saccharide isomerate (saccharide isomerate) as an active ingredient.
7. The cosmetic composition according to claim 6, wherein the composition is used for improving skin elasticity, dryness, or aging symptoms by inhibiting the decomposition ability of hyaluronic acid.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR10-2021-0028329 | 2021-03-03 | ||
| KR1020210028329A KR102548896B1 (en) | 2021-03-03 | 2021-03-03 | Cosmetic composition for skin improvement through control of porphyrin production and hyaluronic acid degradation enzyme |
| PCT/KR2022/002286 WO2022186513A1 (en) | 2021-03-03 | 2022-02-16 | Cosmetic composition for skin care through porphyrin production control and hyaluronidase control in skin microbiome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116940333A true CN116940333A (en) | 2023-10-24 |
Family
ID=83154591
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202280016884.2A Pending CN116940333A (en) | 2021-03-03 | 2022-02-16 | Cosmetic composition for improving skin by regulating porphyrin production of skin resident bacteria and regulating hyaluronidase |
Country Status (4)
| Country | Link |
|---|---|
| JP (1) | JP2024508524A (en) |
| KR (1) | KR102548896B1 (en) |
| CN (1) | CN116940333A (en) |
| WO (1) | WO2022186513A1 (en) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050019354A1 (en) * | 2003-07-23 | 2005-01-27 | Perricone Nicholas V. | Topical benfotiamine treatments |
| KR20060108567A (en) * | 2006-07-26 | 2006-10-18 | 주식회사 코씨드바이오팜 | Cosmetic composition containing solanum tuberosum and/or allium sativum extract |
| KR20180024026A (en) * | 2015-07-23 | 2018-03-07 | 마리 케이 인코포레이티드 | Topical skin formulations |
| TW201924701A (en) * | 2017-11-29 | 2019-07-01 | 美商通路實業集團國際公司 | Method and topical composition for modification of a skin microbiome |
| CN112672728B (en) * | 2018-09-11 | 2023-10-27 | 联合利华知识产权控股有限公司 | Topical compositions comprising saccharide isomerate for microbiome balance |
| US11529300B2 (en) * | 2019-07-03 | 2022-12-20 | Jamrm, Llc | Formulations for enhancing skin firmness, density and thickness |
| CN111773161B (en) * | 2020-06-16 | 2022-11-08 | 广州优理氏生物科技有限公司 | Prebiotic composition and preparation method and application thereof |
-
2021
- 2021-03-03 KR KR1020210028329A patent/KR102548896B1/en active IP Right Grant
-
2022
- 2022-02-16 JP JP2023553374A patent/JP2024508524A/en active Pending
- 2022-02-16 CN CN202280016884.2A patent/CN116940333A/en active Pending
- 2022-02-16 WO PCT/KR2022/002286 patent/WO2022186513A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| KR102548896B1 (en) | 2023-06-27 |
| KR20220124540A (en) | 2022-09-14 |
| JP2024508524A (en) | 2024-02-27 |
| WO2022186513A1 (en) | 2022-09-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102362055B1 (en) | A cosmetic composition for skin improvement comprising polysaccharides, yeast extracts and fermentation of strain having probiotics properties | |
| US20050084553A1 (en) | Composition containing moutan root bark extract as active ingredient | |
| KR102194315B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising centella asiatica fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR100962052B1 (en) | Cosmetic Composition for Improving the Acne containing Lactobacillus rhamnosus or its Culture Medium As Active Ingredient | |
| JP2000247864A (en) | Cosmetic composition | |
| US20220079854A1 (en) | Personal Care Compositions | |
| KR20220018523A (en) | A cosmetic composition for skin improvement comprising polysaccharides, yeast extracts and fermentation of strain having probiotics properties | |
| KR20120081365A (en) | Antibacterial composition containing vitidis vinferae radix, symplocos prunifolia, and campylotropis macrocarpa extracts | |
| KR101020535B1 (en) | The cosmetic composion prepared to the lotus fermented water | |
| CN116940333A (en) | Cosmetic composition for improving skin by regulating porphyrin production of skin resident bacteria and regulating hyaluronidase | |
| KR101739646B1 (en) | A composition for treatment and prevention of acne | |
| KR20190048933A (en) | Cosmetic Composition Comprising Extracts of Colostrum for Improving Skin Wrinkle | |
| MX2015000275A (en) | Use of zinc coceth sulfate as an antibacterial agent against propionibacterium acnes. | |
| KR100642939B1 (en) | Bathroom soap comprising plum extracts and extracting method thereof | |
| CN108498399B (en) | Compound plant extract with antiseptic effect and application thereof in cosmetic antiseptic | |
| WO2017113263A1 (en) | Novel use of gluconacetobacter xylinus fermentation broth as cosmetic composition | |
| KR102227751B1 (en) | Natural antiseptic substitute comprising extraction mixture of Schisandra chinensis, Thymus quinquecostatus and Elsholtzia splendens as effective component and uses thereof | |
| KR102194314B1 (en) | Antioxidant or skin microbiome balance cosmetic composition comprising green tea fermented extract fermented by inoculating lactobacillus rhamnosus strain | |
| KR20190048885A (en) | Composition for improving microbial flora containing extract of Coicis Semen | |
| US20240082125A1 (en) | Use of a short chain fatty acid as antidandruff agent | |
| KR20240031902A (en) | Skin external composition containing an 1,3-propanediol as an active ingredient for maintaining microbiome balance in the skin | |
| KR102001237B1 (en) | Composition for improving microbial flora containing extract of Dolichoris Semen | |
| JP2022526951A (en) | Use of dianhydrohexitol to eliminate the cosmetic effects of acne, dandruff and stinks | |
| Pringgenies et al. | Hair cosmetic ingredients from the symbiont bacteria Xylocarpus sp. fruit are based on antimicrobial and antifungal bacteria | |
| CN114555040A (en) | Cosmetic preparation with anisic acid and levulinic acid with selective antimicrobial activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |